NO2773633T3 - - Google Patents

Info

Publication number
NO2773633T3
NO2773633T3 NO12777930A NO12777930A NO2773633T3 NO 2773633 T3 NO2773633 T3 NO 2773633T3 NO 12777930 A NO12777930 A NO 12777930A NO 12777930 A NO12777930 A NO 12777930A NO 2773633 T3 NO2773633 T3 NO 2773633T3
Authority
NO
Norway
Application number
NO12777930A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2773633T3 publication Critical patent/NO2773633T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Hydrogenated Pyridines (AREA)
NO12777930A 2011-11-02 2012-10-29 NO2773633T3 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11187553 2011-11-02
EP12777930.4A EP2773633B1 (en) 2011-11-02 2012-10-29 Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
PCT/EP2012/071352 WO2013064450A1 (en) 2011-11-02 2012-10-29 Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof

Publications (1)

Publication Number Publication Date
NO2773633T3 true NO2773633T3 (cs) 2017-12-30

Family

ID=47073464

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12777930A NO2773633T3 (cs) 2011-11-02 2012-10-29

Country Status (34)

Country Link
US (4) US8759349B2 (cs)
EP (1) EP2773633B1 (cs)
JP (1) JP6091513B2 (cs)
KR (1) KR102006612B1 (cs)
CN (2) CN106279110B (cs)
AP (1) AP2014007670A0 (cs)
AU (1) AU2012331274B2 (cs)
BR (1) BR112014010583A2 (cs)
CA (1) CA2854217C (cs)
CL (1) CL2014001047A1 (cs)
CO (1) CO6940429A2 (cs)
CY (1) CY1120974T1 (cs)
DK (1) DK2773633T3 (cs)
EA (1) EA025158B9 (cs)
EC (1) ECSP14001929A (cs)
ES (1) ES2645744T3 (cs)
GE (1) GEP20186880B (cs)
HR (1) HRP20171614T1 (cs)
HU (1) HUE034929T2 (cs)
IL (1) IL232035A (cs)
LT (1) LT2773633T (cs)
ME (1) ME02905B (cs)
MX (1) MX348522B (cs)
NO (1) NO2773633T3 (cs)
PE (1) PE20141607A1 (cs)
PH (1) PH12014500970B1 (cs)
PL (1) PL2773633T3 (cs)
PT (1) PT2773633T (cs)
RS (1) RS56498B1 (cs)
SG (1) SG11201401907TA (cs)
SI (1) SI2773633T1 (cs)
TN (1) TN2014000180A1 (cs)
UA (1) UA115868C2 (cs)
WO (1) WO2013064450A1 (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
NO2773633T3 (cs) * 2011-11-02 2017-12-30
CA2915633A1 (en) 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
JP6449870B2 (ja) * 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
ES2702288T3 (es) 2014-10-07 2019-02-28 Vertex Pharma Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
SG11201703284XA (en) * 2014-10-24 2017-06-29 Ono Pharmaceutical Co Kcnq2-5 channel activator
WO2016112120A1 (en) * 2015-01-07 2016-07-14 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
EP4211171A2 (en) 2020-09-10 2023-07-19 Precirix N.V. Antibody fragment against fap
CN112107580A (zh) * 2020-09-29 2020-12-22 北京鑫开元医药科技有限公司 一种脾酪氨酸激酶抑制剂的制剂组合物及其制备方法
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6812003A (cs) 1967-09-07 1969-03-11
US3953476A (en) 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
ATE390414T1 (de) 1999-07-19 2008-04-15 Univ North Carolina Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
WO2001052902A1 (en) 2000-01-24 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
US7956059B2 (en) 2004-08-18 2011-06-07 Parion Sciences, Inc. Aliphatic amide and ester pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
KR101335884B1 (ko) * 2006-07-24 2013-12-12 인터내셔날 스템 셀 코포레이션 망막 줄기 세포로부터 유래한 합성 각막
ES2361595T3 (es) * 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
WO2009074575A2 (en) 2007-12-10 2009-06-18 Novartis Ag Organic compounds
CN102015662A (zh) * 2008-05-13 2011-04-13 诺瓦提斯公司 3,5-二氨基-6-氯-吡嗪-2-甲酸衍生物和它们作为上皮钠通道阻断剂用于治疗气道疾病的用途
CN102112130A (zh) 2008-06-10 2011-06-29 诺瓦提斯公司 作为上皮钠通道阻滞剂的吡嗪衍生物
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
SI2723176T1 (sl) 2011-06-27 2017-09-29 Parion Sciences, Inc. Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala
NO2773633T3 (cs) 2011-11-02 2017-12-30
EP2773624A1 (en) 2011-11-02 2014-09-10 Boehringer Ingelheim International GmbH Novel process for the preparation of acylguanidines and acylthioureas

Also Published As

Publication number Publication date
US20140228374A1 (en) 2014-08-14
IL232035A (en) 2017-05-29
HUE034929T2 (en) 2018-03-28
US8759349B2 (en) 2014-06-24
PE20141607A1 (es) 2014-11-23
CA2854217C (en) 2019-12-31
CN106279110A (zh) 2017-01-04
MX2014005166A (es) 2014-05-28
CN104024244B (zh) 2016-09-14
US20150336933A1 (en) 2015-11-26
PH12014500970A1 (en) 2014-06-09
RS56498B1 (sr) 2018-01-31
TN2014000180A1 (en) 2015-09-30
EP2773633B1 (en) 2017-08-02
PH12014500970B1 (en) 2017-10-06
EA201400521A1 (ru) 2014-09-30
EP2773633A1 (en) 2014-09-10
LT2773633T (lt) 2017-11-10
GEP20186880B (en) 2018-07-25
ECSP14001929A (es) 2015-11-30
JP6091513B2 (ja) 2017-03-08
US20130109697A1 (en) 2013-05-02
SI2773633T1 (sl) 2017-11-30
CA2854217A1 (en) 2013-05-10
EA025158B1 (ru) 2016-11-30
US20180194747A1 (en) 2018-07-12
CY1120974T1 (el) 2019-12-11
UA115868C2 (uk) 2018-01-10
CN106279110B (zh) 2019-12-10
DK2773633T3 (da) 2017-11-13
KR20140085498A (ko) 2014-07-07
SG11201401907TA (en) 2014-05-29
CL2014001047A1 (es) 2014-11-07
CN104024244A (zh) 2014-09-03
KR102006612B1 (ko) 2019-08-02
CO6940429A2 (es) 2014-05-09
PT2773633T (pt) 2017-11-14
WO2013064450A1 (en) 2013-05-10
MX348522B (es) 2017-06-16
ES2645744T3 (es) 2017-12-07
HRP20171614T1 (hr) 2017-12-01
EA025158B9 (ru) 2018-03-30
IL232035A0 (en) 2014-05-28
BR112014010583A2 (pt) 2020-04-22
ME02905B (me) 2018-10-20
NZ622469A (en) 2016-08-26
PL2773633T3 (pl) 2018-01-31
US9920035B2 (en) 2018-03-20
AP2014007670A0 (en) 2014-05-31
AU2012331274A1 (en) 2014-04-03
JP2014534222A (ja) 2014-12-18
HK1196819A1 (zh) 2014-12-24
AU2012331274B2 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
BR112013022641A2 (cs)
BR112013031251A2 (cs)
BR112013027245A2 (cs)
BR112013024383A2 (cs)
BR112013023185A2 (cs)
BR112013022995A2 (cs)
BR112013026905A2 (cs)
BR112013017670A2 (cs)
BR112013027830A2 (cs)
AP3853A (cs)
BR112013026744A2 (cs)
BR112013023927A2 (cs)
BR112013027452A2 (cs)
BR112013024365A2 (cs)
BR112013028733A2 (cs)
BR112013027121A2 (cs)
AP2016009466A0 (cs)
BR112013024588A2 (cs)
BR112013031556A2 (cs)
BR112013026790A2 (cs)
BR112013032368A2 (cs)
BR112013032380A2 (cs)
BR112013032377A2 (cs)
BR112013027836A2 (cs)
BR112013018949A2 (cs)